Combination Therapies for Brain Tumors
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 219
Special Issue Editors
Interests: neurological surgery; nervous system injury and repair; brain tumor
Interests: neuro-genomics (rare neurological disorders and complex traits); pharmacogenomics (efficacy, toxicity/ADR and PK/metabolism of neurology and neuro-oncology drugs); brain tumor registry and biobanking; translational neurology-oncology (therapeutic target validation and clinical trials)
Special Issue Information
Dear Colleagues,
Combination therapies for brain tumors represent a promising and multifaceted approach in the ongoing battle against this devastating disease. The complexity and heterogeneity of brain tumors pose significant challenges for single-modality treatments. However, by strategically combining different therapeutic strategies, such as surgery, radiation therapy, chemotherapy, targeted therapies and immunotherapy, researchers and clinicians can effectively target multiple aspects of tumor growth and progression.
Surgery remains a cornerstone in brain tumor treatment, providing maximal tumor resection and alleviating mass effects. Following surgery, radiation therapy can be employed to target residual tumor cells and prevent recurrence, while chemotherapy may be utilized to eradicate systemic metastases and infiltrative tumor cells beyond the surgical field. Emerging targeted therapies, focusing on specific molecular alterations in tumor cells, offer personalized treatment options and minimize off-target effects. Additionally, immunotherapies aim to harness the body's immune system to recognize and destroy tumor cells, showing great promise in several types of brain tumors.
By integrating these diverse treatment modalities, clinicians can achieve synergistic effects and significantly improve patient outcomes. Moreover, such tailored approaches consider the unique characteristics of each patient's tumor, optimizing therapeutic responses. As research advances, combination therapies hold tremendous potential to transform the landscape of brain tumor management, offering hope for increased survival rates and enhanced quality of life for patients and their families.
With this Special Issue, we aim to curate the most recent, innovative and ground-breaking research on brain tumors, encompassing glioblastomas, metastatic brain tumors and low-grade gliomas, while covering surgical, clinical and bio-molecular advances. The ultimate goal is to promote novel and effective treatments for this deadly disease. Therefore, we warmly welcome contributions from surgeons, radiation oncologists, neuro-oncologists, pathologists, molecular biologists and all professionals involved in high-grade glioma research. Together, we can drive progress and bring new hope to those affected by brain tumors.
Dr. Jason H. Huang
Dr. Ekokobe Fonkem
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- novel diagnostics
- therapies
- glioblastoma
- meningioma
- astrocytoma
